NeoTX Therapeutics

NeoTX Therapeutics, established in 2004 and headquartered in Rehovot, Israel, specializes in developing innovative anticancer immunotherapies. The company's core technology, Selective T cell Redirection (STR) platform, targets tumors by redirecting immune cells to mount a powerful, safe, and native antibacterial response. NeoTX's approach involves binding a genetically engineered bacterial determinant to the tumor surface, activating immune cells away from the suppressive tumor environment, and converting a weak immune response into an effective one. The company's strategy focuses on building a proprietary product pipeline through independent research and development, as well as collaborative partnerships and license agreements.